Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Physicians are voicing growing frustration with payer policies that delay payments, deny necessary care and add administrative burdens. From preauthorization headaches to reimbursement struggles, nine ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

If you’re considering enrolling in a Medicare Advantage plan (also known as Medicare Part C) in Colorado to meet your various ...

Enter your email address to follow this blog and receive notifications of new posts by email.